Resources Investment Advisors Inc. boosted its stake in shares of Pfizer (NYSE:PFE) by 80.5% in the 4th quarter, HoldingsChannel reports. The fund owned 20,532 shares of the biopharmaceutical company’s stock after buying an additional 9,154 shares during the period. Resources Investment Advisors Inc.’s holdings in Pfizer were worth $743,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Investment Partners Ltd. OH ADV lifted its position in Pfizer by 5.9% during the fourth quarter. Investment Partners Ltd. OH ADV now owns 33,784 shares of the biopharmaceutical company’s stock valued at $1,224,000 after purchasing an additional 1,873 shares during the last quarter. Chicago Equity Partners LLC lifted its position in Pfizer by 2.7% during the fourth quarter. Chicago Equity Partners LLC now owns 259,690 shares of the biopharmaceutical company’s stock valued at $9,406,000 after purchasing an additional 6,850 shares during the last quarter. Savant Capital LLC lifted its position in Pfizer by 4.4% during the fourth quarter. Savant Capital LLC now owns 54,941 shares of the biopharmaceutical company’s stock valued at $1,990,000 after purchasing an additional 2,300 shares during the last quarter. Telos Capital Management Inc. bought a new position in Pfizer during the fourth quarter valued at $265,000. Finally, Callahan Advisors LLC lifted its position in Pfizer by 0.7% during the fourth quarter. Callahan Advisors LLC now owns 291,717 shares of the biopharmaceutical company’s stock valued at $10,566,000 after purchasing an additional 1,941 shares during the last quarter. 71.20% of the stock is owned by institutional investors.
Several research firms have commented on PFE. Nord/LB reiterated a “neutral” rating on shares of Pfizer in a research report on Tuesday, January 2nd. Jefferies Group set a $39.00 target price on shares of Pfizer and gave the stock a “hold” rating in a report on Monday, February 26th. Morgan Stanley set a $41.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Friday, January 5th. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, January 8th. Finally, Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $37.98 target price for the company in a report on Monday, January 8th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $39.25.
PFE stock opened at $35.17 on Monday. The stock has a market capitalization of $209,362.27, a P/E ratio of 13.27, a P/E/G ratio of 1.76 and a beta of 0.90. Pfizer has a 12 month low of $31.67 and a 12 month high of $39.43. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The firm’s revenue was up .6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.47 EPS. equities research analysts expect that Pfizer will post 2.96 EPS for the current fiscal year.
Pfizer declared that its board has approved a stock buyback program on Monday, December 18th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.
ILLEGAL ACTIVITY WARNING: “Pfizer (PFE) Shares Bought by Resources Investment Advisors Inc.” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3343026/pfizer-pfe-shares-bought-by-resources-investment-advisors-inc.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.